A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma

Hiroyuki Kanzaki, Fumiaki Shinohara, Maiko Suzuki, Satoshi Wada, Yutaka Miyamoto, Yuuki Yamaguchi, Yuta Katsumata, Seicho Makihira, Toshi Kawai, Martin A Taubman, Yoshiki Nakamura

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Interferon-gamma (IFN-γ) is a pleiotropic cytokine that exerts anti-tumor and anti-osteoclastogenic effects. Although transcriptional and post-transcriptional regulation of IFN-γ is well understood, subsequent modifications of secreted IFN-γ are not fully elucidated. Previous research indicates that some cancer cells escape immune surveillance and metastasize into bone tissue by inducing osteoclastic bone resorption. Peptidases of the a-disintegrin and metalloproteinase (ADAM) family are implicated in cancer cell proliferation and tumor progression. We hypothesized that the ADAM enzymes expressed by cancer cells degrades IFN-γ and attenuates IFN-γ-mediated anti-tumorigenic and anti-osteoclastogenic effects. Recombinant ADAM17 degraded IFN-γ into small fragments. The addition of ADAM17 to the culture supernatant of stimulated mouse splenocytes decreased IFN-γ concentration. However, ADAM17 inhibition in the stimulated mouse T-cells prevented IFN-γ degradation. ADAM17-expressing human breast cancer cell lines MCF-7 and MDA-MB-453 also degraded recombinant IFN-γ, but this was attenuated by ADAM17 inhibition. Degraded IFN-γ lost the functionality including the inhibititory effect on osteoclastogenesis. This is the first study to demonstrate the extracellular proteolytic degradation of IFN-γ by ADAM17. These results suggest that ADAM17-mediated degradation of IFN-γ may block the anti-tumorigenic and anti-osteoclastogenic effects of IFN-γ. ADAM17 inhibition may be useful for the treatment of attenuated cancer immune surveillance and/or bone metastases.

Original languageEnglish (US)
Pages (from-to)32259
JournalScientific Reports
Volume6
DOIs
StatePublished - Aug 30 2016
Externally publishedYes

Fingerprint

Disintegrins
Metalloproteases
Interferon-gamma
Neoplasms
Bone and Bones
ADAM17 Protein
Bone Resorption
Osteogenesis

Keywords

  • ADAM17 Protein/genetics
  • Amino Acid Sequence
  • Animals
  • Antibodies, Monoclonal/immunology
  • Antibodies, Neutralizing/immunology
  • Breast Neoplasms/genetics
  • Cell Line, Tumor
  • Cells, Cultured
  • Humans
  • Interferon-gamma/genetics
  • MCF-7 Cells
  • Mice
  • Mice, Inbred BALB C
  • Proteolysis/drug effects
  • RAW 264.7 Cells
  • RNA Interference
  • Recombinant Proteins/metabolism
  • T-Lymphocytes/drug effects

Cite this

Kanzaki, H., Shinohara, F., Suzuki, M., Wada, S., Miyamoto, Y., Yamaguchi, Y., ... Nakamura, Y. (2016). A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma. Scientific Reports, 6, 32259. https://doi.org/10.1038/srep32259

A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma. / Kanzaki, Hiroyuki; Shinohara, Fumiaki; Suzuki, Maiko; Wada, Satoshi; Miyamoto, Yutaka; Yamaguchi, Yuuki; Katsumata, Yuta; Makihira, Seicho; Kawai, Toshi; Taubman, Martin A; Nakamura, Yoshiki.

In: Scientific Reports, Vol. 6, 30.08.2016, p. 32259.

Research output: Contribution to journalArticle

Kanzaki, H, Shinohara, F, Suzuki, M, Wada, S, Miyamoto, Y, Yamaguchi, Y, Katsumata, Y, Makihira, S, Kawai, T, Taubman, MA & Nakamura, Y 2016, 'A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma', Scientific Reports, vol. 6, pp. 32259. https://doi.org/10.1038/srep32259
Kanzaki, Hiroyuki ; Shinohara, Fumiaki ; Suzuki, Maiko ; Wada, Satoshi ; Miyamoto, Yutaka ; Yamaguchi, Yuuki ; Katsumata, Yuta ; Makihira, Seicho ; Kawai, Toshi ; Taubman, Martin A ; Nakamura, Yoshiki. / A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma. In: Scientific Reports. 2016 ; Vol. 6. pp. 32259.
@article{3aa423724c4743af836f00d7f412c831,
title = "A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma",
abstract = "Interferon-gamma (IFN-γ) is a pleiotropic cytokine that exerts anti-tumor and anti-osteoclastogenic effects. Although transcriptional and post-transcriptional regulation of IFN-γ is well understood, subsequent modifications of secreted IFN-γ are not fully elucidated. Previous research indicates that some cancer cells escape immune surveillance and metastasize into bone tissue by inducing osteoclastic bone resorption. Peptidases of the a-disintegrin and metalloproteinase (ADAM) family are implicated in cancer cell proliferation and tumor progression. We hypothesized that the ADAM enzymes expressed by cancer cells degrades IFN-γ and attenuates IFN-γ-mediated anti-tumorigenic and anti-osteoclastogenic effects. Recombinant ADAM17 degraded IFN-γ into small fragments. The addition of ADAM17 to the culture supernatant of stimulated mouse splenocytes decreased IFN-γ concentration. However, ADAM17 inhibition in the stimulated mouse T-cells prevented IFN-γ degradation. ADAM17-expressing human breast cancer cell lines MCF-7 and MDA-MB-453 also degraded recombinant IFN-γ, but this was attenuated by ADAM17 inhibition. Degraded IFN-γ lost the functionality including the inhibititory effect on osteoclastogenesis. This is the first study to demonstrate the extracellular proteolytic degradation of IFN-γ by ADAM17. These results suggest that ADAM17-mediated degradation of IFN-γ may block the anti-tumorigenic and anti-osteoclastogenic effects of IFN-γ. ADAM17 inhibition may be useful for the treatment of attenuated cancer immune surveillance and/or bone metastases.",
keywords = "ADAM17 Protein/genetics, Amino Acid Sequence, Animals, Antibodies, Monoclonal/immunology, Antibodies, Neutralizing/immunology, Breast Neoplasms/genetics, Cell Line, Tumor, Cells, Cultured, Humans, Interferon-gamma/genetics, MCF-7 Cells, Mice, Mice, Inbred BALB C, Proteolysis/drug effects, RAW 264.7 Cells, RNA Interference, Recombinant Proteins/metabolism, T-Lymphocytes/drug effects",
author = "Hiroyuki Kanzaki and Fumiaki Shinohara and Maiko Suzuki and Satoshi Wada and Yutaka Miyamoto and Yuuki Yamaguchi and Yuta Katsumata and Seicho Makihira and Toshi Kawai and Taubman, {Martin A} and Yoshiki Nakamura",
year = "2016",
month = "8",
day = "30",
doi = "10.1038/srep32259",
language = "English (US)",
volume = "6",
pages = "32259",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma

AU - Kanzaki, Hiroyuki

AU - Shinohara, Fumiaki

AU - Suzuki, Maiko

AU - Wada, Satoshi

AU - Miyamoto, Yutaka

AU - Yamaguchi, Yuuki

AU - Katsumata, Yuta

AU - Makihira, Seicho

AU - Kawai, Toshi

AU - Taubman, Martin A

AU - Nakamura, Yoshiki

PY - 2016/8/30

Y1 - 2016/8/30

N2 - Interferon-gamma (IFN-γ) is a pleiotropic cytokine that exerts anti-tumor and anti-osteoclastogenic effects. Although transcriptional and post-transcriptional regulation of IFN-γ is well understood, subsequent modifications of secreted IFN-γ are not fully elucidated. Previous research indicates that some cancer cells escape immune surveillance and metastasize into bone tissue by inducing osteoclastic bone resorption. Peptidases of the a-disintegrin and metalloproteinase (ADAM) family are implicated in cancer cell proliferation and tumor progression. We hypothesized that the ADAM enzymes expressed by cancer cells degrades IFN-γ and attenuates IFN-γ-mediated anti-tumorigenic and anti-osteoclastogenic effects. Recombinant ADAM17 degraded IFN-γ into small fragments. The addition of ADAM17 to the culture supernatant of stimulated mouse splenocytes decreased IFN-γ concentration. However, ADAM17 inhibition in the stimulated mouse T-cells prevented IFN-γ degradation. ADAM17-expressing human breast cancer cell lines MCF-7 and MDA-MB-453 also degraded recombinant IFN-γ, but this was attenuated by ADAM17 inhibition. Degraded IFN-γ lost the functionality including the inhibititory effect on osteoclastogenesis. This is the first study to demonstrate the extracellular proteolytic degradation of IFN-γ by ADAM17. These results suggest that ADAM17-mediated degradation of IFN-γ may block the anti-tumorigenic and anti-osteoclastogenic effects of IFN-γ. ADAM17 inhibition may be useful for the treatment of attenuated cancer immune surveillance and/or bone metastases.

AB - Interferon-gamma (IFN-γ) is a pleiotropic cytokine that exerts anti-tumor and anti-osteoclastogenic effects. Although transcriptional and post-transcriptional regulation of IFN-γ is well understood, subsequent modifications of secreted IFN-γ are not fully elucidated. Previous research indicates that some cancer cells escape immune surveillance and metastasize into bone tissue by inducing osteoclastic bone resorption. Peptidases of the a-disintegrin and metalloproteinase (ADAM) family are implicated in cancer cell proliferation and tumor progression. We hypothesized that the ADAM enzymes expressed by cancer cells degrades IFN-γ and attenuates IFN-γ-mediated anti-tumorigenic and anti-osteoclastogenic effects. Recombinant ADAM17 degraded IFN-γ into small fragments. The addition of ADAM17 to the culture supernatant of stimulated mouse splenocytes decreased IFN-γ concentration. However, ADAM17 inhibition in the stimulated mouse T-cells prevented IFN-γ degradation. ADAM17-expressing human breast cancer cell lines MCF-7 and MDA-MB-453 also degraded recombinant IFN-γ, but this was attenuated by ADAM17 inhibition. Degraded IFN-γ lost the functionality including the inhibititory effect on osteoclastogenesis. This is the first study to demonstrate the extracellular proteolytic degradation of IFN-γ by ADAM17. These results suggest that ADAM17-mediated degradation of IFN-γ may block the anti-tumorigenic and anti-osteoclastogenic effects of IFN-γ. ADAM17 inhibition may be useful for the treatment of attenuated cancer immune surveillance and/or bone metastases.

KW - ADAM17 Protein/genetics

KW - Amino Acid Sequence

KW - Animals

KW - Antibodies, Monoclonal/immunology

KW - Antibodies, Neutralizing/immunology

KW - Breast Neoplasms/genetics

KW - Cell Line, Tumor

KW - Cells, Cultured

KW - Humans

KW - Interferon-gamma/genetics

KW - MCF-7 Cells

KW - Mice

KW - Mice, Inbred BALB C

KW - Proteolysis/drug effects

KW - RAW 264.7 Cells

KW - RNA Interference

KW - Recombinant Proteins/metabolism

KW - T-Lymphocytes/drug effects

U2 - 10.1038/srep32259

DO - 10.1038/srep32259

M3 - Article

C2 - 27573075

VL - 6

SP - 32259

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

ER -